Literature DB >> 30846499

Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.

Daniel A Pollyea1, Chelsea Harris2,3, Jennifer L Rabe1, Brenna R Hedin2,3, Lesly De Arras3, Sigrid Katz4, Emily Wheeler4, Rafael Bejar4, Matthew J Walter5, Craig T Jordan1, Eric M Pietras1, Scott Alper6,3,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30846499      PMCID： PMC6717580          DOI： 10.3324/haematol.2018.214155

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

Review 1.  Innate immune signaling in the myelodysplastic syndromes.

Authors:  Daniel T Starczynowski; Aly Karsan
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 2.  Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  J Natl Cancer Inst       Date:  2013-09-19       Impact factor: 13.506

Review 3.  Inflammatory signals regulate hematopoietic stem cells.

Authors:  Megan T Baldridge; Katherine Y King; Margaret A Goodell
Journal:  Trends Immunol       Date:  2011-01-11       Impact factor: 16.687

4.  Interleukin-6 and interleukin-1 enhancement of GM-CSF-dependent proliferation of haematopoietic progenitor cells in myelodysplastic syndromes.

Authors:  M R Schipperus; P Sonneveld; J Lindemans; K van Lom; M Vlastuin; J Abels
Journal:  Br J Haematol       Date:  1991-04       Impact factor: 6.998

5.  IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.

Authors:  Damien Reynaud; Eric Pietras; Keegan Barry-Holson; Alain Mir; Mikhail Binnewies; Marion Jeanne; Olga Sala-Torra; Jerald P Radich; Emmanuelle Passegué
Journal:  Cancer Cell       Date:  2011-11-15       Impact factor: 31.743

6.  Comparative genomics RNAi screen identifies Eftud2 as a novel regulator of innate immunity.

Authors:  Lesly De Arras; Rebecca Laws; Sonia M Leach; Kyle Pontis; Jonathan H Freedman; David A Schwartz; Scott Alper
Journal:  Genetics       Date:  2013-12-20       Impact factor: 4.562

Review 7.  Risks for infection in patients with myelodysplasia and acute leukemia.

Authors:  Livio Pagano; Morena Caira
Journal:  Curr Opin Infect Dis       Date:  2012-12       Impact factor: 4.915

8.  An evolutionarily conserved innate immunity protein interaction network.

Authors:  Lesly De Arras; Amara Seng; Brad Lackford; Mohammad R Keikhaee; Bruce Bowerman; Jonathan H Freedman; David A Schwartz; Scott Alper
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

Review 9.  Impact of interleukin-6 in hematological malignancies.

Authors:  Renate Burger
Journal:  Transfus Med Hemother       Date:  2013-07-19       Impact factor: 3.747

10.  Limiting of the innate immune response by SF3A-dependent control of MyD88 alternative mRNA splicing.

Authors:  Lesly De Arras; Scott Alper
Journal:  PLoS Genet       Date:  2013-10-24       Impact factor: 5.917
View more
  15 in total

1.  Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.

Authors:  Anacélia Matos; Silvia M M Magalhães; Michael J Rauh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.

Authors:  Anne Sophie Kubasch; Uwe Platzbecker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

3.  NF-κB mediates lipopolysaccharide-induced alternative pre-mRNA splicing of MyD88 in mouse macrophages.

Authors:  Frank Fang-Yao Lee; Kevin Davidson; Chelsea Harris; Jazalle McClendon; William J Janssen; Scott Alper
Journal:  J Biol Chem       Date:  2020-03-16       Impact factor: 5.157

4.  Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs.

Authors:  Tomoya Muto; Callum S Walker; Kwangmin Choi; Kathleen Hueneman; Molly A Smith; Zartash Gul; Guillermo Garcia-Manero; Averil Ma; Yi Zheng; Daniel T Starczynowski
Journal:  Nat Immunol       Date:  2020-04-20       Impact factor: 25.606

5.  Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.

Authors:  Carolien Duetz; Theresia M Westers; Florentien E M In 't Hout; Eline M P Cremers; Canan Alhan; Bianca Venniker-Punt; Heleen A Visser-Wisselaar; Dana A Chitu; Aniek O de Graaf; Linda Smit; Joop H Jansen; Arjan A van de Loosdrecht
Journal:  Br J Haematol       Date:  2021-03-25       Impact factor: 6.998

Review 6.  Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes.

Authors:  Luana Chiquetto Paracatu; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

7.  CtIP -mediated alternative mRNA splicing finetunes the DNA damage response.

Authors:  Rosario Prados-Carvajal; Guillermo Rodriguez-Real; Gabriel Gutierrez-Pozo; Pablo Huertas
Journal:  RNA       Date:  2020-12-09       Impact factor: 4.942

Review 8.  Inflammaging, an Imbalanced Immune Response That Needs to Be Restored for Cancer Prevention and Treatment in the Elderly.

Authors:  Juana Serrano-López; Beatriz Martín-Antonio
Journal:  Cells       Date:  2021-09-28       Impact factor: 6.600

Review 9.  Emerging roles of spliceosome in cancer and immunity.

Authors:  Hui Yang; Bruce Beutler; Duanwu Zhang
Journal:  Protein Cell       Date:  2021-07-01       Impact factor: 15.328

10.  MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.

Authors:  Daniel A Pollyea; Hyun Min Kim; Brett M Stevens; Frank Fang-Yao Lee; Chelsea Harris; Brenna R Hedin; Jennifer R Knapp; Brian P O'Connor; Craig T Jordan; Eric M Pietras; Aik Choon Tan; Scott Alper
Journal:  J Leukoc Biol       Date:  2020-11-06       Impact factor: 6.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.